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Abstract 
ERCC1 is a DNA repair protein that forms a heterodimer with XPF. The resultant 
dimer is active in multiple systems of DNA repair. Mutations in this repair 
mechanism result in progeroid syndromes, such as Xeroderma Pigmentosum. 
These syndromes present with progressive neurodegeneration and are modeled 
by deletion or transgenic knock down of the ERCC1 gene in mice. Global 
knockouts and Ercc1-/Δ mice, in which only 5% of the normal compliment of 
ERCC1 is expressed, have been studied in order to elucidate the cause of the 
neural pathology. These models, similar to patients, often show 
neurodegeneration, but it was unclear whether this loss was due to a primary 
neuronal dysfunction or that of supporting glial cells. L7Cre;Ercc1-/cond mice, in 
which Ercc1-XPF is deleted only in the neurons of the forebrain, are used in this 
study to determine the cell autonomous impact of DNA repair deficiency on 
neurons. Oxidative damage is thought to contribute to the progression of aging-
 v 
related neurodenerative disease, such as AD and PD, and DNA could be a 
prominent target. The hypothesis that pathology in L7Ercc1-/cond mice is similar to 
that of neurodegenerative disease states was supported in many instances. The 
decrease in weight seen in mutant mice is also seen in patients with both AD and 
PD. The degeneration in the hippocampus and alteration in DG proliferation is 
consistent with that often seen in AD, as is cortical degeneration and thinning of 
the corpus callosum. Gliosis in the striatum is seen in many PD patients and 
could be contributing to the ambulation impairment seen in the mutant mice. 
These data suggest a link between DNA repair deficiency and 
neurodegeneration stemming from multiple origins.  Elucidating the impact of 
unrepaired endogenous DNA damage on neurons using this genetic tool may 
allow for the development of future interventions to slow aging-related 
neurodegeneration, as well as the progression of AD and PD. 
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Introduction 
Aging is frequently associated with the risk of developing 
neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s 
disease (AD) (Eller et al. 2001, Kaup et al. 2011).  AD is characterized by 
memory impairment associated with volume loss in regions such as the 
hippocampus (Kaup et al., 2011). PD is characterized by a loss of dopaminergic 
neurons in the substantia nigra, resulting in motor impairment and dysfunction, 
such as tremor (Braak et al., 2002). Successful cognitive aging in the absence of 
neurodegenerative disease is positively correlated with the volume of certain 
brain structures (Kaup et al., 2011). Global brain volume is positively correlated 
with overall cognition, while hippocampal volume is associated with memory 
function. This would suggest that a decrease in cell number is a crucial factor in 
cognitive decline (Kaup et al., 2011). Oxidative damage is one current theory 
about the cause of cell loss and cognitive/memory dysfunction commonly 
associated with aging. Hamilton et al. (2001) showed a correlation with age and 
increased oxidative DNA damage in multiple strains of rodents. DNA damage is 
also causal to the pathologies in DNA repair deficiency syndromes, such as 
xeroderma pigmentosum (XP) and ataxia telangiectasia, which include 
progressive neurological degeneration (Borgesius et al. 2011, McNeil et al. 
2012).  Given the link between cell loss and DNA damage in aging and disease 
states such as XP, characterization of the effects of this damage on neurons may 
contribute to treatment intervention in the future. Murine models of DNA repair 
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deficiency syndromes provide a unique opportunity to elucidate the effect of DNA 
damage on brain structures and function. 
ERCC1 
Ercc1 is a DNA repair protein involved in nucleotide excision repair, 
interstrand crosslink repair, and double-strand break repair (Niedernhofer et al., 
2004). Ercc1 dimerizes with the protein XPF to interact with DNA (figure 1) 
(McNeil et al., 2012, Tsodikov et al., 2005). Ercc1 and XPF are found in a 
mutated form in nucleotide excision repair disorders such as XP, resulting in 
sensitivity to UV damage, as well as endogenous DNA damage (McNeil et al., 
2012). The Ercc1-/- murine model is used to characterize the effects of DNA 
repair deficiency in a premature aging system (McWhir et al. 1993). These mice, 
however, age so quickly that their lifespan is reduced to only approximately 4 
weeks (Nevedomskaya et al., 2010, Niedernhofer et al., 2006). Ercc1-/Δ mice 
have some protein function remaining, slowing the progression of aging. Analysis 
of neural pathology in these mice demonstrates increased glial response 
throughout many areas of the brain (de Waard et al., 2010). Preliminary data 
generated by the Greenamyer lab suggest that in the substantia nigra region of 
Ercc1-/Δ mice, such reactive gliosis is present, consistent with neurodegeneration 
and increased oxidative stress, but no frank loss of dopaminergic neurons (figure 
2). Although the absence of cell loss is a different pathological manifestation than 
that characteristic of PD, these data suggest that there is neural injury, 
nonetheless. This implies a possible underlying link between DNA repair 
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deficiency and neurodegenerative disease. There is also a decrease in the size 
and an irregularity in the shape of nerve fibers in the Ercc1-/Δ model, as 
demonstrated by Goss et al. (2011) (Figure 3). Other neuronal pathologies found 
in Ercc1-/Δ mice include degeneration in motor neurons of the spinal cord, 
Purkinje cells of the cerebellum, hippocampal neurons and axons of fiber tracts, 
such as the corpus callosum (Borgesius et al., 2011, de Graaf et al., 2013, de 
Waard et al., 2010). The symptomatology in the substantia nigra and the 
peripheral nervous system could account for the ambulation impairment seen in 
these mice. Although there are marked neural alterations throughout the brain, 
Ercc1-/Δ mice develop symptoms spanning multiple organs, including kidney and 
liver impairments (Dolle et al. 2006, Nevedomskaya et al., 2010). The Ercc1-/cond 
mice utilized in this study (L7Ercc1-/cond) have mutations limited to neurons of the 
forebrain in order to more narrowly characterize the importance of DNA repair to 
cognition. We hypothesize that there will be degeneration in brain structures that 
are also commonly affected by neurodegenerative disease states such as AD 
and PD.  
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Figure 1 taken from McNeil et al. 2012: Three-dimensional model of helix-hairpin-helix configuration
in the ERCC1-XPF dimer 
Figure 2 . Work from the lab of Dr. Greenamyre demonstrating increased oxidation (blue) in the ERCC1 -/delta mice.
An increase in GFAP (green) is also seen. The presence of characterstic TH stain (red) con!rms that the a"ected 
area is the substantia nigra. 
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Figure 3 adapted from Goss et al, 2011. Micrographs depict the crosssection of the sciatic nerve in a 20 week 
control mouse (A), a 20 week Ercc1-/Δ  mouse (B), and a 120 week old control mouse (C). D, E, and F 
are magni"ed imagesof the boxed area in the cross-sections above. The 20 week old Ercc1-/Δ  mouse has a
signi"cant decrease in the thickness of individual nerve "bers and an irregularity in shape when compared
to a control mouse of the same age. This phenotype is similar to, but more exaggerated than that seen in an 
aged control mouse.
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Objectives 
 
Although previous studies in mice and humans have demonstrated that 
deficiency of Ercc1-XPF DNA repair endonuclease has a profound effect on the 
nervous system, it is not clear what the mechanism of neurodegeneration is.  
Using transgenic mice in which only neurons are lacking Ercc1-XPF activity, the 
objectives of this study are: 
1) To determine if the animals suffer from a primary 
neurodegeneration, i.e., if loss of neurons is a cell-autonomous 
event. 
2) To determine which areas of the brain are affected by DNA 
repair deficiency, which will reveal which neurons are 
hypersensitive to oxidative DNA damage. 
3)  To characterize cellular changes in the neurons of these areas 
 
4)  To compare and contrast these changes with age-related degenerative 
diseases 
 
If these goals are accomplished, it will establish a link between endogenous 
DNA damage and neurodegeneration that may be pertinent to common age-
related CNS diseases. The mechanism of neurodegeneration in inherited DNA 
repair deficiency syndromes will also be elucidated. This lays the groundwork for 
developing rationale strategies for disease treatment or prevention in the future 
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Methods 
 
Mice 
 
Mice were housed in the animal facility of Hillman Cancer Center 
UPMC and given food and water ad libitum. The Division of Laboratory Animal 
Research guidelines and IACUC approved protocols were utilized. 
Brains were analyzed from CamKIIα-Cre;Ercc1-/cond  (L7Ercc1-/cond ) and control 
littermate mice at 2.5 months, 9.5 months, 10 months, and 11.7 months for Ki-
67 staining, a marker of cell proliferation. Five mutant mice and five controls 
were assessed (one of each genotype at each age point). For GFAP, TH and 
nissl stain, ten L7Ercc1-/cond and ten control littermate mice were analyzed (one 
of each genotype at 2.5, 9, 9.5, 10.3, 11, 11.7, and 13.7 months. two of each 
genotype were analyzed at 10 months. One mouse of each genotype at 2 
months of age was used to assess cell death). An early time point was used in 
order to assess cell death before much of the degeneration had already 
occurred. 
Behavioral Tests 
 
Motor coordination was tested using the rotarod system. Mice were given 
a week of training on the system in order to decrease anxiety. Animals were 
tested weekly thereafter. A speed of 15 revolutions per minute was used. The 
time to fall was recorded. 
Immunohistochemistry 
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Brains were fixed in 4% paraformaldehyde and subsequently 
cryoprotected in a solution of 30% sucrose. Brains were then cryosectioned and 
placed in wells of 1x PBS with 0.2% azide until further processing. Floating 
sections were prepared for immunostaining by blocking for 1 hour at room 
temperature in a solution of 5% normal donkey serum in 1% triton PBS. Tissues 
were then incubated in primary antibody (diluted in 5% normal donkey serum in 
1% triton PBS) at 4°C overnight, washed in 1% triton PBS, 1xPBS, and 
subsequently incubated in secondary antibody (diluted in 1% normal donkey 
serum in 1% triton PBS) for 1 hour at room temperature.  After washes in 1x 
PBS, tissues were mounted onto slides and coverslipped via fluormount.  
Primary antibodies used include tyrosine hydroxylase (TH, ab9702, 1:250), ki-67 
(ab9260, 1:350), and glial acidic fibrillary protein (GFAP, ab4674, 1:350). 
Secondary antibodies include d-light 488, cy3 and cy5. 
 BrdU 
One L7Ercc1-/cond mouse and one control mouse at 3 months of age were 
injected for one week with BrdU. Brains were dissected, flash frozen and 
subsequently cryosectioned in a sequential manner onto superfrost plus slides 
and stored at -20°C. Tissues were fixed for 15 minutes in 2% paraformaldehyde 
and subsequently stained for BrdU expression.   After fixation, tissues were 
washed in PBS and incubated for 15 minutes in 0.1% triton PBS. Tissues were 
washed in PBS and blocked in 2% BSA for 45 minute. After washes in 0.5% BSA 
tissues were incubated in anti-BrdU at 1:250 dilution for 1 hour at room 
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temperature. Subsequent washes in 0.5% BSA were carried out and then tissues 
were incubated in secondary for 1 hour at room temperature. Tissues were 
washed in 0.5% BSA and then 1x PBS and hoecht stain applied. After final 
washes, tissues were coverslipped with gelvatol.  
TUNEL Assay 
To detect cell death a roche TUNEL assay kit was used. After initial washes with 
1x PBS, cells were incubated in TUNEL mixture for 20 minutes and room 
temperature. This mixture consisted of 90ul of dH2O, 64ul of TdT buffer, 40ul 
CoCl2, 2ul TdT, and 2 ul biotin. Tissues were then washed with 1xPBS and 
streptavidin cy3 antibody was applied for 30 minutes at room temperature. After 
washes with 1x PBS tissues were coverslipped with gelvatol.  
 
         Nissl Stain 
Tissues were serially hydrated via 3-minute washes in 100% ethanol, 
xylenes, 100% ethanol, 70% ethanol, and 20% ethanol. Tissues were then 
washed for 5 minutes in dH2O and subsequently incubated in 0.1% cresyl violet 
solution for 5 minutes. After washes in dH2O, tissues were serially dehydrated 
via 20% ethanol, 100% ethanol and xylenes.  
Imaging 
  Slides were analyzed via the Nikon 90i upright tiling scope. Images were 
taken at 20x magnification and stitched to create larger views. Images were 
analyzed via Nikon elements software.  
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Results 
 
Phenotype Overview 
 
Figure 4 demonstrates some key phenotypic features of the L7Ercc1-/cond 
mutant mice. At around 8.5 months, mutant mice exhibit compulsive scratching of 
the head and ears to the point of self-mutilation, causing open wounds on the 
neck region, apparent in figure 4A and 4C. The cerebral atrophy caused by the 
Ercc1 mutation at 10 months is evident in Figure 4B and in the middle images of 
Figure 4C. Stars in Figure 4C mark the regions that clearly elucidate cortical 
shrinkage in mutant mice, revealing the midbrain. It appears that the cerebellums 
of these mice are not atrophied, which is to be expected due to normal Ercc1 
expression in this structure. 
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Body Weight  
 A graph of the body weights of mutant mice compared to littermate controls 
across time shows that at 8 months, the mutants start to lose weight (Figure 5a). 
These controls include mice that are heterozygous for Ercc1 expression, as they 
do not present with a phenotype. This weight loss increases with age, becoming 
lowest at 10 months. This symptom presents around the time neural changes 
become evident. 
A
B
C
Figure 4 . A) Images demonstrate obsessive scratching, causing the open wounds visible on mutant mice. 
B) Brain of mutant mouse (left )and control mouse (right) of the same age demonstrate the decrease in size 
of the mutant brains. This size decrease is seen significtanly in the cortex (star- midbrain is more visable in
mutant mouse due to cortical atrophy). C) Far left image further depicts the scratch wounds mutant mice inflict 
on themselves. Middle images show mutant brain (left) and control brain (right) of the same age inside of skull 
to further demonstratecortical atrophy. 
* *
10 months oldL7ERCC1-/c
10 months
L7+/-
10 months
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Survival 
 A decrease in survival percentage was seen in mutant mice at approximately 5 
months of age and progressed steadily to the point of zero survival, around 18 
months. Control mice do not begin to decline in survival until after 16 months and 
maintain above a 50% survival percentage at 18 months (Figure 15b). 
W
ei
gh
t (
g)
L7Cre+/-E1-/c
Controls
Age (mo)
Figure 5a: Graph demonstrates weights of L7 mice compared to littermates, 
including ERCC1+/- mice. 
 13 
 
Balance and Coordination 
 Ambulation was assessed using the rotarod system.  Young mutant mice have 
comparable ambulation ability to control mice (Figure 6B), implied by similar time 
spent on the rotarod. However, older L7Ercc1-/cond mice (>6mo) have an impaired 
ability to maintain balance and coordination on the rotarod system (Figure 6A, B).  
Figure 5b. Graph demonstrates survival percentages of L7ERCC1-/c mice (red, n=24) versus
controls (blue, n=13). A clear decrease in survival percentage is seen in mutant mice around
age 5 mo and steadily declines. Controls do not start to decrease in survival until after age 
16 mo. At survival percentage of zero for mutant mice,  above 50% of controls remain.
Lifespan
A
liv
e 
(%
)
Age (months)
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A
B
Young L7 (<4mo) Old L7 (>6mo
Figure 6. A) Bar graph demonstrates a signi!cant decrease in the time coordinated movement can
be maintained on the rotarod by old mutant mice (>6mo, n=2) compared to young mice of the same
genotype (<4 mo, n=5). B) Line graph demonstrates similar performance between young mutant mice
(red) and control mice (blue, n=5). However, a signi!cant decrease in ambulation is demonstrated by
old mutant mice (green). 
L7 Rotarod Test- Age Comparison
Trial Number
L7 Rotarod Test- Age Comparison
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Hippocampus 
Glial Response  
 In order to localize inflammatory response to neural damage, tissues were 
stained with GFAP. L7Ercc1-/cond and control mice had a comparable level of 
gliosis in the hippocampus at 2.5 months of age. At 9.5 moths and on, an 
increased level of GFAP staining was seen in the hippocampal region of mutant 
mice when compared to control mice (Figure 7A). Zoomed image of GFAP in 
Figure 7B more clearly demonstrates this glial response in the CA1, CA3 and 
dentate gyrus. Although images were taken at the same magnification, 
neurodegeneration in the mutant hippocampus makes more of the structure 
visible in the field of view when compared to control mice.  These data suggest 
that hippocampal neurons are susceptible to damage when DNA repair is 
deficient. 
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Control
2.5 mo
9.5 mo
10 mo
11.7 mo
L7 ERCC1 -/c
DG
CA3
CA1
*
*
*
*
*
*
*
*
*
*
*
*
A
CA3
CA1
DG
CA3
CA1
DG
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Cell Death Assay  
 TUNEL assay signal, measuring fragmented DNA, appears higher in the CA1, 
CA3 and dentate gyral regions (stars mark areas of interest) of mutant mice at 
2.5 months of age (Figure 8). Although there is some signal in the control mice, 
there is a higher intensity and more punctate staining in the mutant mice, 
indicating higher cell death. The highest level of cell death appears to be in the 
dentate gyrus (DG). These results are cohesive with the neural damage 
L7 ERCC1-/c Control
11.7 mo
B
Figure 7) 20x  A) GFAP staining shows an increase in glial cells in mutant mice
after age 2.5 months in the hippocampus. B) zoomed image shows glial
staining increase more clearly
CA3 CA3
CA1
CA1
DG
DG
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suggested by the increased in GFAP signal in the region. 
 
 
Cellular characterization 
  In order to characterize neuronal shape and number, tissues were stained 
with nissl. Further cellular characterization was accomplished though BrdU 
staining and other immunohistochemical assessments.  
  A decrease in cell density was seen in the CA1 and CA3 regions after the 2.5- 
month time point in mutant mice (Figure 9A, B). At 11.7 months, the 
L7 ERCC1-/c
Control
DG
CA3
CA1
DG
CA1
CA3
*
*
*
*
*
*
Figure 8. TUNEL stain in the hippocampus is more intense in the regions of interest
(stars) in the mutant mice compared to controls. 
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degeneration in the mutant mice appears to spread to the dentate gyrus (DG) 
(Figure 9A, C). This cell loss is consistent with increased gliosis seen after 2.5 
months in mutant mice. 
  Enlarged cells, which are likely dying neurons, were seen beneath the 
subgranular zone of the DG in these mice as well. Because this region is home 
to the progenitor cells of the hippocampal formation, tissues were stained with Ki-
67 to assess proliferation levels. 
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L7 ERCC1 -/c
2.5 mo
9.5 mo
11.7 mo
control
CA3
CA1 *
*
*
*
*
10mo
A
*
CA3
CA1 CA1
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CA1
CA3
CA3CA3
CA3
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*
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*
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 At 2.5 months of age, proliferation in the two genotypes appears to be 
comparable (figure 10). However, with increasing age, Ki-67 signal seems to 
escalate in the mutant mice. In order to assess whether this increase in signal 
could be due to compensation for the degeneration in mutant mice or due to glial 
proliferation in response to neural injury, Ki-67 was combined with GFAP staining 
(figure 11). The signal overlay does not appear to show Ki-67 directly overlapping 
with GFAP. However, Ki-67 signal appears to become unspecific in the mutant 
mice with increasing age. This unspecific signal is frequently high in the region 
beneath the subgranular zone, in which the nissl demonstrated enlarged neurons 
(Figure 9C). This suggests that the extensive neurodegeneration seen in the 
L7 ERCC1 -/c control
11.7mo
C
Figure 9. A) Nissl stain shows that after 2.5 months of age there is decrease in the 
cellularity of the CA1 and CA3 regions of the hippocampus in mutant mice (*).
Swollen cells appear in the subgranular layer of mutant mice with 
increasing age as well (circle). B) A zoomed image of the CA1 and CA3 regions 
in mice of 11.7 months further demonstrates this cell loss in mutant mice (*). C) Zoomed 
image  depicts swollen cells  inside the dentage gyrus in mutant mice at 11.7 months.
DG
DG
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mutant mice may be the cause of unspecific Ki-67 labeling. In order to attain 
more specific labeling, BrdU injections were given to one mutant and one control 
mouse as described previously and the brain tissue was subsequently stained for 
BrdU.  
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2.5 mo
L7 ERCC1 -/c
9.5mo
10 mo
11.7 mo
control
DG
DG
DG
*
Figure 10. ki-67 staining demonstrates that at 2.5 months, proliferation
is comparable between the two genotypes. After that time point the 
ki-67 stain appears to become less speci!c, especially in the mutant mice.
Much of the unspeci!c staining seems to be labeling the neurons that
coincide with the swollen neurons seen in the dentage gyrus via 
nissl stain (circle).
DG
DG DG
DG DG
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Control
2.5 mo
9.5 mo
10 mo
11.7 mo
L7 ERCC1 -/c
DG
CA3
CA1
*
*
*
*
*
*
*
*
*
*
*
*
Figure 11. GFAP (green) and ki-67 (red) overlap shows no direct relationship
between the unspeci!c ki-67 signal and an increase in glia (stars mark points 
of higher ki-67 signal in the regions of interest). 
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 The BrdU signal appeared to be similar in the subgranular zone, home of the 
hippocampal progenitor cells, of the mutant mouse compared to control mouse at 
3 months (Figure 12A). This finding indicates similar neurogenesis in the two 
genotypes at a young age. Due to the length of the injection period, BrdU signal 
could be expected in the granular layer of the DG due to migration of the newly 
proliferated cells from the subgranular layer. In this layer, however, the signal is 
almost negligible in the mutant when compared to the control mouse. This 
suggests that the proliferated cells in the hippocampus of L7Ercc1-/cond mice 
degenerate before or shortly after replacing the current neurons in the DG and, 
therefore, cannot be located with BrdU staining. A higher magnification image of 
the DG (Figure 12B) shows that there is less overlap (purple signal, exemplified 
in square regions) between BrdU (red) and DAPI (blue) in the mutant than in the 
control mouse. The continued death of the newly proliferated cells could 
contribute to the decrease in cell number seen in the DG of older mutant mice. 
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DG
BRDU DAPI
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L7 ERCC1 -/c
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A
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Corpus Callosum  
Cellular Characterization 
 At the age of 2.5 months, the thickness of the corpus callosum as measured 
via nissl stain did not differ significantly between the two genotypes. However, at 
9.5 months, the corpus callosum of the mutant mice appears to have a 
decreased fiber density compared to control mice (figure 13A). The borders of 
the corpus callosum are also less evident, making the fiber tract less 
recognizable in older mutants. The degeneration in the corpus callosum is 
Figure 12. A) 20x, BRDU staining shows an increase in proliferation in cells of the control hippocampus. 
There is also a decrease in the proliferated cells traveling to the dentate gyrus in the mutant mice. 
B) 40x image more clearly shows higher overlap of BRDU (red) with DAPI (blue) con!rming higher 
nuclear stain in control mice (square demonstrates region of overlap).
B
L7 ERCC1 -/c
control
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progressive, as the appearance of the corpus callosum is severely altered in 11.7 
month-old L7Ercc1-/cond mice when compared to controls of the same age (figure 
13A). In addition to thinning of the tract, there appears to be an increase in 
cellularity of the corpus callosum in these mice compared to control mice. The 
increase appears most dramatic at or beyond 10 months of age (Figure 13B). 
GFAP staining suggests this may be due to a glial response in the area due to 
degeneration (Figure 14A). Gliosis appears to be most dramatic at the 11.7-
month stage (Figure 14B). This inflammation is consistent with the atrophy seen 
at this time point in mutant mice.  
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ControlL7 ERCC1 -/c
CC CC
B
Figure 13. A) Nissl stain of the corpus collosum demonstrates thinning
of the tract occurs in mutants after age 2.5 months. Zoomed area 
(squares) are shown in B. The zoomed image shows an increase in
cellular labeling (dark puncta) and a decrease in thickness (red lines)
 in the mutant mice. This increase appears to be most dramatic after 
9.5 months.
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 Cortex and Striatum 
Inflammation response 
 Analysis of GFAP staining shows an increase in glia in the cortex and striatum 
of L7Ercc1-/cond mice (Figure 15). This increase was most apparent at 10 months 
and older. 
ERCC1 -/c control
11.7 mo
CC CC
Figure 14. 20x A) Immunohistochemistry demonstrates an increase in 
GFAP in the corpus collosum in mutant mice 9.5 months and after. 
B) zoomed image of GFAP staining more clearly demonstrates the 
increase in the corpus collosum of mutant mice. 
B
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Substantia Nigra 
Cell death assay 
 TUNEL assay in the substantia nigra at age 2.5 months (Figure 16) shows no 
overlap in either mutant or control mice with the TH neurons of the substantia 
nigra. TH is utilized to ensure accuracy of location to the presence of the protein 
in dopaminergic neurons. Figure 16B more clearly demonstrates lack of 
colocalizatiion between the two signals. Although there appear to be less TH 
neurons in the mutant mice, this is likely a plane-of-section phenomenon.  These 
L7 ERCC1-/c
10 mo
control
CX
STR
STR
CX
CC
CC
Figure 15. 20x image of GFAP staining in 10 mo mice demonstrates an increase in glial 
response in mutant mice when compared to controls. 
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data suggest that at 2.5 months, there is no cell death in the substantia nigra.
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Control
L7 ERCC1 -/c
Figure 16. A) 20x Images demonstrate that there is no TUNEL stain (red) that colocalizes with
the nuclei of TH neurons (green) in the substantia nigra. Although there are less
TH neurons in the mutant mouse in this image, this is likely a plane-of-section phenomenon. B)
Zoomed image of the substantia nigra smore clearly shows lack of overlap between the nuclear 
TUNEL stain (red) and TH (green).
B
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Discussion 
 Ercc1 mutation leads to a progressive decrease in weight in mice starting at 8 
months of age (Figure 5). Because the Ercc1 mutation is limited to neurons in the 
model being testing, it is unlikely that this weight loss is caused by primary 
dysfunction in the gastrointestinal epithelia. Weight loss is frequently a symptom 
in PD and AD as well (Zussy et al. 2013, Secher et al. 2012, Chen et al. 2003). 
This suggests that similar systemic effects occur in these neurodegenerative 
disease states and that of DNA repair deficiency, supporting the hypothesis 
previously presented.  
  Macroscopic cortical pathology in L7Ercc1-/cond mice is evident at 
approximately 10 months of age. Reactive gliosis often occurs in response to 
such neural injury (Glass et al., 2010).  Therefore, increased GFAP staining seen 
in the hippocampus suggests that there is similar degeneration in this structure. 
The presence of degeneration is supported by a decrease in the cellularity of the 
CA1, CA3 and dentate gyral regions seen via nissl stain in mutant mice. It is 
likely that memory function is significantly decreased in these mice, similar to that 
seen in AD. 
  Degeneration in the hippocampus was again confirmed by an increase in 
TUNEL assay signal in L7Ercc1-/cond mice, highest in the DG. The decreased 
cellularity is likely not caused by a lack of adult neurogenesis via progenitor cells 
in the subgranular layer, as suggested by a comparable BrdU signal in this 
region in both mutant and control mice. The neuronal degeneration in the DG 
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occurring at 11.7 months may be a result of the loss of the newly proliferated 
cells. It is possible that replacement of the DG neurons by neurogenesis is 
sufficient to prevent an obvious cell loss in that area until the degeneration 
becomes more extensive with age. Lack of BrdU signal in the granular layer of 
mutant mice, however, would suggest that his proliferation level is below that of 
significant immunohistochemical detection. 
 The decreased cellularity in the hippocampus of L7Ercc1-/cond mice is similar to 
the degeneration seen in AD. The hippocampal proliferation effects, however, are 
currently variable among AD models and patients. Some studies demonstrate a 
decrease in proliferation with AD, while others show an increase (Jin et al., 2004, 
Lazarov and Marr, 2010, Winner et al., 2011). It is possible that the increase in 
proliferation signal in the latter studies is a result of glial response to the 
neurodegeneration (Winner et al., 2011). The increase in proliferation could also 
be explained by neural compensation to the degeneration (Winner et al., 2011. 
Jin et al., 2004).  It is likely that the second scenario is the cause of the increased 
proliferation in the L7Ercc1 mutant mice, as the GFAP staining does not 
colocalize with the ki-67 signal.  Despite the uncertainty, similarities in the 
hippocampal degeneration in our model to that in AD pathology may suggest a 
link between DNA repair deficiency and cell loss in neurodegenerative diseases. 
 In addition to the hippocampus, pathology was seen in the corpus callosum of 
L7Ercc1-/cond mice. This fiber pathway is crucial for communication between 
hemispheres of the brain, significant in the connection of cortical neurons (Teipel 
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et al., 2002). The L7Ercc1 mutant mice show a thinning of this tract, likely due to 
degeneration of axons from cortical neurons.  The mutant mice also show an 
increased cellularity in the corpus callosum. It is possible that the reactive gliosis 
that occurs in response to neurodegeneration, as demonstrated by an increased 
in GFAP staining, is the cause of this increase. The corpus callosum is quite 
often affected in many patients with AD as well, manifested as a thinning of the 
tract (Alves et al., 2012, Teipel et al. 2002). This phenomenon supports the 
hypothesis previously suggested and provides another link between DNA repair 
and common neurodegenerative disease pathologies.  
 Degeneration in the corpus callosum has been linked to the level of cortical 
degeneration in certain studies of AD (Teipel et al., 2002). This association is 
supported in the pathology of our model, given the large decrease in cortical 
brain mass seen in mutant mice at a macroscopic level. The glial response in the 
cortical region of L7Ercc1-/cond mice is consistent with cortical injury as well. 
Cortical degeneration is another link between the pathologies of DNA repair 
deficiency and that of neurodegenerative diseases. There is often cortical 
thinning in patients with AD (Becker et al., 2011, Grand’Maison et al., 2013, 
Chang et al., 2013). Grand’Maison et al. (2013) demonstrated that this thinning 
could also be correlated with susceptibility to subsequent amyloid-B deposition.  
 L7Ercc1-/cond mutant mice had impairment in ambulation when tested via 
rotarod. Although similar dysfunction is seen in PD models, it is predominantly 
caused by neuronal loss in the substantia nigra. The degeneration in this disease 
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is thought primarily to be a result of the presence of Lewy bodies in the 
dopaminergic neurons. However, it has been suggested that reactive oxygen 
species contribute to its progression (Ghosh et al., 2012, Ghosh et al., 2009). 
The L7Ercc1 mutant mice did not appear to have degeneration in the substantia 
nigra, as suggested by an absence of TUNEL stain colocalizing with the TH stain 
of the structure. The presence of oxidative damage in global Ercc1 transgenic 
mice (Ercc1-/Δ mice)(Figure 2), however, suggests that if a TUNEL stain were 
performed on tissues from older mice the results may show increased cell death. 
This possibility is currently being explored. Given that the Ercc1-/Δ mice also have 
peripheral neuropathy (Goss et al., 2011), it will be necessary to analyze nerve 
fibers in the L7Ercc1-/cond mice as an appropriate control.  
 The nigro-striatal circuit is also crucial for regular ambulation (Pradhan et al. 
2013). The increase in GFAP signal in the striatum of mutant mice could 
contribute to the ambulation phenotype in the absence of substantia nigra 
degeneration. Neuroinflammation is seen in the striatum of many PD patients in 
addition to that in the substantia nigra, providing another link between 
pathologies due to DNA repair deficiency and those of neurodegenerative 
disease states (Gerhard et al., 2006, McGeer et al., 1988). It is thought that the 
neuroinflammation commonly associated with neurodegenerative disease states 
such as AD and PD actually impedes neural recovery (Pradhan et al. 2013 
 The hypothesis that DNA repair deficiency would cause pathology in the 
structures often affected in neurodegenerative disease states, such as AD and 
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PD, was supported in many instances during analysis. The hypothesis is not 
currently supported when analyzing degeneration in the substantia nigra of the 
mutant mice; however this neuronal death may be seen in older mutant mice. 
Given the many parallels between the patterns of degeneration in DNA repair 
deficient mice and that seen in PD and AD, it would be interesting to further 
elucidate the role of DNA repair in these patients. Future experiments include 
quantifying the cell loss in the hippocampus and additional characterization of the 
proliferation in mutant mice via BrdU injections. TEM analysis is also being 
performed on various regions of interest in mutant and control mice, which will 
elucidate ultrastructural changes due to DNA repair. Another interesting facet of 
this project to explore will be determining the root of the obsessive scratching.  
 The results of this study suggest that a repair deficiency could be facilitating 
the degeneration of neurons in common neurodegenerative disease systems. If 
confirmed, this fact could present a point for intervention- an opportunity to 
attempt the retardation of degeneration in these patients through the expression 
of Ercc1. The link between repair deficiency and neurodegeneration is an area 
that will likely provide interesting data for future studies.  
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